New Tool for Monitoring Molecular Response in Patients with Chronic Myeloid Leukemia

Talha Badar, Rajyalakshmi Luthra, Hagop Kantarjian, Elias Jabbour, Gautam Borthakur, Guillermo Garcia-Manero, Xuelin Huang, Rajesh Singh, Brittany Alvarez, Bradley Austermiller, Tom B. Morrison, Keyur P. Patel, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Objective: Chronic myeloid leukemia treatment monitoring using polymerase chain reaction-based peripheral blood testing of t 9;22 BCR-ABL1 provides improved test sensitivity over cytology but suffers from inadequate standardization in most laboratories due to variations inherent in the existing polymerase chain reaction methodologies. We performed the initial analytic performance evaluation of a novel competitive template-based peripheral blood b2a2/b3a2 transcript abundance method, called standardized nucleic acid quantification (SNAQ) test, with hypothesis that this will produced more consistent results with less frequent interlaboratory variations. Materials and Methods: Thirty-six chronic myeloid leukemia patients treated at our institution were enrolled. We compared SNAQ test with 2 laboratory developed test at the MD Anderson molecular diagnostic laboratory and Cancer Genetics Institute for analyzing BCR-ABL1 from peripheral blood samples. Each test result (n=36) was ranked against all the other samples tested by the same method. Results: The Pearson correlation between SNAQ and laboratory developed test done at 2 labs was met by correlations of 0.97, 0.96, 0.96, and 0.94. Analysis of variance of log %BCR-ABL1 interlaboratory results indicated no significant difference (P=0.98). Post hoc analysis of method agreement showed the SNAQ method had a 95% limit of agreement of ±3-fold between laboratories. Conclusions: In this pilot study, SNAQ methodology performed consistent with half-log accuracy. Additional studies from a larger sample size and correlation with clinical outcomes are required to confirm this observation.

Original languageEnglish (US)
Pages (from-to)33-39
Number of pages7
JournalApplied Immunohistochemistry and Molecular Morphology
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nucleic Acids
Polymerase Chain Reaction
Molecular Pathology
Sample Size
Cell Biology
Analysis of Variance
Neoplasms
Therapeutics

Keywords

  • BCR-ABL1
  • CML
  • molecular diagnostics
  • SNAQ test

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Medical Laboratory Technology

Cite this

New Tool for Monitoring Molecular Response in Patients with Chronic Myeloid Leukemia. / Badar, Talha; Luthra, Rajyalakshmi; Kantarjian, Hagop; Jabbour, Elias; Borthakur, Gautam; Garcia-Manero, Guillermo; Huang, Xuelin; Singh, Rajesh; Alvarez, Brittany; Austermiller, Bradley; Morrison, Tom B.; Patel, Keyur P.; Cortes, Jorge.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 27, No. 1, 01.01.2019, p. 33-39.

Research output: Contribution to journalArticle

Badar, T, Luthra, R, Kantarjian, H, Jabbour, E, Borthakur, G, Garcia-Manero, G, Huang, X, Singh, R, Alvarez, B, Austermiller, B, Morrison, TB, Patel, KP & Cortes, J 2019, 'New Tool for Monitoring Molecular Response in Patients with Chronic Myeloid Leukemia', Applied Immunohistochemistry and Molecular Morphology, vol. 27, no. 1, pp. 33-39. https://doi.org/10.1097/PAI.0000000000000526
Badar, Talha ; Luthra, Rajyalakshmi ; Kantarjian, Hagop ; Jabbour, Elias ; Borthakur, Gautam ; Garcia-Manero, Guillermo ; Huang, Xuelin ; Singh, Rajesh ; Alvarez, Brittany ; Austermiller, Bradley ; Morrison, Tom B. ; Patel, Keyur P. ; Cortes, Jorge. / New Tool for Monitoring Molecular Response in Patients with Chronic Myeloid Leukemia. In: Applied Immunohistochemistry and Molecular Morphology. 2019 ; Vol. 27, No. 1. pp. 33-39.
@article{ef9631728b82458fb28e3806c23de183,
title = "New Tool for Monitoring Molecular Response in Patients with Chronic Myeloid Leukemia",
abstract = "Objective: Chronic myeloid leukemia treatment monitoring using polymerase chain reaction-based peripheral blood testing of t 9;22 BCR-ABL1 provides improved test sensitivity over cytology but suffers from inadequate standardization in most laboratories due to variations inherent in the existing polymerase chain reaction methodologies. We performed the initial analytic performance evaluation of a novel competitive template-based peripheral blood b2a2/b3a2 transcript abundance method, called standardized nucleic acid quantification (SNAQ) test, with hypothesis that this will produced more consistent results with less frequent interlaboratory variations. Materials and Methods: Thirty-six chronic myeloid leukemia patients treated at our institution were enrolled. We compared SNAQ test with 2 laboratory developed test at the MD Anderson molecular diagnostic laboratory and Cancer Genetics Institute for analyzing BCR-ABL1 from peripheral blood samples. Each test result (n=36) was ranked against all the other samples tested by the same method. Results: The Pearson correlation between SNAQ and laboratory developed test done at 2 labs was met by correlations of 0.97, 0.96, 0.96, and 0.94. Analysis of variance of log {\%}BCR-ABL1 interlaboratory results indicated no significant difference (P=0.98). Post hoc analysis of method agreement showed the SNAQ method had a 95{\%} limit of agreement of ±3-fold between laboratories. Conclusions: In this pilot study, SNAQ methodology performed consistent with half-log accuracy. Additional studies from a larger sample size and correlation with clinical outcomes are required to confirm this observation.",
keywords = "BCR-ABL1, CML, molecular diagnostics, SNAQ test",
author = "Talha Badar and Rajyalakshmi Luthra and Hagop Kantarjian and Elias Jabbour and Gautam Borthakur and Guillermo Garcia-Manero and Xuelin Huang and Rajesh Singh and Brittany Alvarez and Bradley Austermiller and Morrison, {Tom B.} and Patel, {Keyur P.} and Jorge Cortes",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/PAI.0000000000000526",
language = "English (US)",
volume = "27",
pages = "33--39",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - New Tool for Monitoring Molecular Response in Patients with Chronic Myeloid Leukemia

AU - Badar, Talha

AU - Luthra, Rajyalakshmi

AU - Kantarjian, Hagop

AU - Jabbour, Elias

AU - Borthakur, Gautam

AU - Garcia-Manero, Guillermo

AU - Huang, Xuelin

AU - Singh, Rajesh

AU - Alvarez, Brittany

AU - Austermiller, Bradley

AU - Morrison, Tom B.

AU - Patel, Keyur P.

AU - Cortes, Jorge

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Chronic myeloid leukemia treatment monitoring using polymerase chain reaction-based peripheral blood testing of t 9;22 BCR-ABL1 provides improved test sensitivity over cytology but suffers from inadequate standardization in most laboratories due to variations inherent in the existing polymerase chain reaction methodologies. We performed the initial analytic performance evaluation of a novel competitive template-based peripheral blood b2a2/b3a2 transcript abundance method, called standardized nucleic acid quantification (SNAQ) test, with hypothesis that this will produced more consistent results with less frequent interlaboratory variations. Materials and Methods: Thirty-six chronic myeloid leukemia patients treated at our institution were enrolled. We compared SNAQ test with 2 laboratory developed test at the MD Anderson molecular diagnostic laboratory and Cancer Genetics Institute for analyzing BCR-ABL1 from peripheral blood samples. Each test result (n=36) was ranked against all the other samples tested by the same method. Results: The Pearson correlation between SNAQ and laboratory developed test done at 2 labs was met by correlations of 0.97, 0.96, 0.96, and 0.94. Analysis of variance of log %BCR-ABL1 interlaboratory results indicated no significant difference (P=0.98). Post hoc analysis of method agreement showed the SNAQ method had a 95% limit of agreement of ±3-fold between laboratories. Conclusions: In this pilot study, SNAQ methodology performed consistent with half-log accuracy. Additional studies from a larger sample size and correlation with clinical outcomes are required to confirm this observation.

AB - Objective: Chronic myeloid leukemia treatment monitoring using polymerase chain reaction-based peripheral blood testing of t 9;22 BCR-ABL1 provides improved test sensitivity over cytology but suffers from inadequate standardization in most laboratories due to variations inherent in the existing polymerase chain reaction methodologies. We performed the initial analytic performance evaluation of a novel competitive template-based peripheral blood b2a2/b3a2 transcript abundance method, called standardized nucleic acid quantification (SNAQ) test, with hypothesis that this will produced more consistent results with less frequent interlaboratory variations. Materials and Methods: Thirty-six chronic myeloid leukemia patients treated at our institution were enrolled. We compared SNAQ test with 2 laboratory developed test at the MD Anderson molecular diagnostic laboratory and Cancer Genetics Institute for analyzing BCR-ABL1 from peripheral blood samples. Each test result (n=36) was ranked against all the other samples tested by the same method. Results: The Pearson correlation between SNAQ and laboratory developed test done at 2 labs was met by correlations of 0.97, 0.96, 0.96, and 0.94. Analysis of variance of log %BCR-ABL1 interlaboratory results indicated no significant difference (P=0.98). Post hoc analysis of method agreement showed the SNAQ method had a 95% limit of agreement of ±3-fold between laboratories. Conclusions: In this pilot study, SNAQ methodology performed consistent with half-log accuracy. Additional studies from a larger sample size and correlation with clinical outcomes are required to confirm this observation.

KW - BCR-ABL1

KW - CML

KW - molecular diagnostics

KW - SNAQ test

UR - http://www.scopus.com/inward/record.url?scp=85021861629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021861629&partnerID=8YFLogxK

U2 - 10.1097/PAI.0000000000000526

DO - 10.1097/PAI.0000000000000526

M3 - Article

C2 - 28682832

AN - SCOPUS:85021861629

VL - 27

SP - 33

EP - 39

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 1

ER -